Literature DB >> 31986411

Transcriptional regulation of PRKAR2B by miR-200b-3p/200c-3p and XBP1 in human prostate cancer.

Lei Xia1, Qing Han2, Chenfei Chi1, Yinjie Zhu1, Jiahua Pan1, Baijun Dong1, Yiran Huang1, Weiliang Xia2, Wei Xue3, Jianjun Sha4.   

Abstract

The cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway is profoundly implicated in Prostate cancer (PCa) progression. Previously, we showed that PRKAR2B, the type II-beta regulatory subunit of PKA, is highly expressed in castration-resistant prostate cancer (CRPC) and can induce epithelial-mesenchymal transition by activating Wnt/β-catenin signaling in PCa cells. However, the molecular mechanism of dysregulated PRKAR2B expression pattern is still largely unknown. In this study, we found that the mutation, copy number alteration, and methylation status of PRKAR2B gene have no correlation with its expression level in PCa. Then, we identified two microRNAs (miR-200b-3p and miR-200c-3p) to be critical regulators of PRKAR2B expression in PCa. Notably, miR-200b-3p and miR-200c-3p expression were significantly downregulated in metastatic CRPC and negatively correlated with the expression level of PRKAR2B in PCa tissues. Moreover, we characterized X-Box Binding Protein 1 (XBP1) as a key transcription factor responsible for PRKAR2B expression in PCa. Importantly, miR-200b-3p/200c-3p or XBP1 knockdown inhibited PCa cell proliferation and promoted cell apoptosis and these inhibitory roles could be largely restored by PRKAR2B, suggesting that PRKAR2B is a functional mediator of miR-200b-3p, miR-200c-3p, and XBP1 in PCa. Collectively, our study firstly identified miR-200b-3p/200c-3p and XBP1 as the critical upstream regulators of PRKAR2B in PCa and provided novel insights to PRKAR2B-driven PCa progression.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  PRKAR2B; Prostate cancer; Transcription factor; XBP1; miR-200b-3p; miR-200c-3p

Year:  2020        PMID: 31986411     DOI: 10.1016/j.biopha.2020.109863

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  13 in total

1.  CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.

Authors:  Xi Chen; Yechen Wu; Xinan Wang; Chengdang Xu; Licheng Wang; Jingang Jian; Denglong Wu; Gang Wu
Journal:  Eur J Med Res       Date:  2022-07-02       Impact factor: 4.981

2.  MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms.

Authors:  Florian Posch; Felix Prinz; Amar Balihodzic; Christian Mayr; Tobias Kiesslich; Christiane Klec; Katharina Jonas; Dominik A Barth; Jakob M Riedl; Armin Gerger; Martin Pichler
Journal:  Cancers (Basel)       Date:  2021-08-08       Impact factor: 6.575

3.  Circular RNA circ_103820 suppresses lung cancer tumorigenesis by sponging miR-200b-3p to release LATS2 and SOCS6.

Authors:  Yongbin Chi; Wenlong Zheng; Guangyu Bao; Lifeng Wu; Xiaoxue He; Ruyi Gan; Yan Shen; Xudong Yin; Mingming Jin
Journal:  Cell Death Dis       Date:  2021-02-15       Impact factor: 8.469

4.  Role of IGF2 in the Study of Development and Evolution of Prostate Cancer.

Authors:  P Porras-Quesada; J M González-Cabezuelo; V Sánchez-Conde; I Puche-Sanz; V Arenas-Rodríguez; C García-López; J F Flores-Martín; J M Molina-Hernández; M J Álvarez-Cubero; L J Martínez-González; F Vázquez-Alonso
Journal:  Front Genet       Date:  2022-01-04       Impact factor: 4.599

5.  MicroRNA-200c-3p Negatively Regulates ATP2A2 and Promotes the Progression of Papillary Thyroid Carcinoma.

Authors:  Yu-Lai Feng; Ting Ke; Gao-Lei Wang; Hai-Yan Qi; Yang Xiao
Journal:  Biochem Genet       Date:  2022-01-25       Impact factor: 2.220

6.  Inhibition of miR-200b-3p alleviates lipid accumulation and promotes cholesterol efflux by targeting ABCA1 in macrophage-derived foam cells.

Authors:  Yu-Ting Wu; Jiang-Bin Li; Hui-Qin Lin; Guo-Xin Zhang; Cong-Min Hong; Ming Li; Zhi-Jun Guo; Yan-Bing Yang
Journal:  Exp Ther Med       Date:  2021-06-03       Impact factor: 2.447

7.  MiR-373 Inhibits the Epithelial-Mesenchymal Transition of Prostatic Cancer via Targeting Runt-Related Transcription Factor 2.

Authors:  Jianyi Pang; Limei Dai; Chen Zhang; Qinglei Zhang
Journal:  J Healthc Eng       Date:  2021-06-29       Impact factor: 2.682

8.  Xiaoai Jiedu Recipe suppresses hepatocellular carcinogenesis through the miR-200b-3p /Notch1 axis.

Authors:  Wenli Qiu; Zhongqiu Wang; Rong Chen; Haibo Shi; Yanxia Ma; Hongli Zhou; Muhan Li; Wenting Li; Haibin Chen; Hongguang Zhou
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

9.  NEAT1/miR-200b-3p/SMAD2 axis promotes progression of melanoma.

Authors:  Wen-Jie Zhou; Hao-Yu Wang; Jie Zhang; Hai-Ying Dai; Zhi-Xian Yao; Zhong Zheng; Sun Meng-Yan; Ke Wu
Journal:  Aging (Albany NY)       Date:  2020-11-16       Impact factor: 5.682

10.  Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.

Authors:  Mireia Olivan; Marta Garcia; Leticia Suárez; Marc Guiu; Laura Gros; Olga Méndez; Marina Rigau; Jaume Reventós; Miguel F Segura; Inés de Torres; Jacques Planas; Xavier de la Cruz; Roger R Gomis; Juan Morote; Ruth Rodríguez-Barrueco; Anna Santamaria
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.